These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 7595746)

  • 21. Clinical and pharmacokinetic overview of parenteral etoposide phosphate.
    Schacter LP; Igwemezie LN; Seyedsadr M; Morgenthien E; Randolph J; Albert E; Santabárbara P
    Cancer Chemother Pharmacol; 1994; 34 Suppl():S58-63. PubMed ID: 8070028
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Assessment of toxicokinetics and toxicodynamics following intravenous administration of etoposide phosphate in beagle dogs.
    Igwemezie LN; Kaul S; Barbhaiya RH
    Pharm Res; 1995 Jan; 12(1):117-23. PubMed ID: 7724471
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial.
    Greco FA; Thompson DS; Morrissey LH; Erland JB; Burris HA; Spigel DR; Joseph G; Corso SW; Spremulli E; Hainsworth JD
    Oncologist; 2005 Oct; 10(9):728-33. PubMed ID: 16249353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Pharmacokinetic, bioavailability, and feasibility study of oral vinorelbine in patients with solid tumors.
    Rowinsky EK; Noe DA; Trump DL; Winer EP; Lucas VS; Wargin WA; Hohneker JA; Lubejko B; Sartorius SE; Ettinger DS
    J Clin Oncol; 1994 Sep; 12(9):1754-63. PubMed ID: 8083697
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bioequivalence study of two formulations of etoposide in advanced lung cancer patients.
    Li D; Liu L
    Int J Clin Pharmacol Ther; 2015 Jun; 53(6):474-9. PubMed ID: 25828637
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetic comparison of oral and intravenous etoposide in patients treated with the CHOEP-regimen for malignant lymphomas.
    Kroschinsky FP; Friedrichsen K; Mueller J; Pursche S; Haenel M; Prondzinsky R; Ehninger G; Schleyer E
    Cancer Chemother Pharmacol; 2008 Apr; 61(5):785-90. PubMed ID: 17579865
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacokinetics and pharmacodynamics of 21-day continuous oral etoposide in pediatric patients with solid tumors.
    Sonnichsen DS; Ribeiro RC; Luo X; Mathew P; Relling MV
    Clin Pharmacol Ther; 1995 Jul; 58(1):99-107. PubMed ID: 7628187
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic study of cisplatin and infusional etoposide phosphate in advanced breast cancer with correlation of response to topoisomerase IIalpha expression.
    Braybrooke JP; Levitt NC; Joel S; Davis T; Madhusudan S; Turley H; Wilner S; Harris AL; Talbot DC
    Clin Cancer Res; 2003 Oct; 9(13):4682-8. PubMed ID: 14581337
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers.
    Berg SL; Blaney SM; Adamson PC; O'Brien M; Poplack DG; Arndt C; Blatt J; Balis FM
    J Clin Oncol; 1998 Jan; 16(1):181-6. PubMed ID: 9440741
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Etoposide phosphate: what, why, where, and how?
    Schacter L
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):1-7. PubMed ID: 8996569
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transdermal Delivery of Etoposide Phosphate I: In Vitro and In Vivo Evaluation.
    Patel H; Joshi A; Joshi A; Stagni G
    J Pharm Sci; 2016 Jul; 105(7):2114-22. PubMed ID: 27233689
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A pharmacoeconomic evaluation of cisplatin in combination with either etoposide or etoposide phosphate in small cell lung cancer.
    Doyle JJ; Dezii CM; Sadana A
    Semin Oncol; 1996 Dec; 23(6 Suppl 13):51-60. PubMed ID: 8996576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.
    Lum BL; Kaubisch S; Yahanda AM; Adler KM; Jew L; Ehsan MN; Brophy NA; Halsey J; Gosland MP; Sikic BI
    J Clin Oncol; 1992 Oct; 10(10):1635-42. PubMed ID: 1403041
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Saturable pharmacokinetics and paclitaxel pharmacodynamics in children with solid tumors.
    Sonnichsen DS; Hurwitz CA; Pratt CB; Shuster JJ; Relling MV
    J Clin Oncol; 1994 Mar; 12(3):532-8. PubMed ID: 7907130
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Bioequivalence of two tablet formulations of capecitabine and exploration of age, gender, body surface area, and creatinine clearance as factors influencing systemic exposure in cancer patients.
    Cassidy J; Twelves C; Cameron D; Steward W; O'Byrne K; Jodrell D; Banken L; Goggin T; Jones D; Roos B; Bush E; Weidekamm E; Reigner B
    Cancer Chemother Pharmacol; 1999; 44(6):453-60. PubMed ID: 10550565
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative pharmacokinetic study of high-dose etoposide and etoposide phosphate in patients with lymphoid malignancy receiving autologous stem cell transplantation.
    Dorr RT; Briggs A; Kintzel P; Meyers R; Chow HH; List A
    Bone Marrow Transplant; 2003 Apr; 31(8):643-9. PubMed ID: 12692603
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A randomised, concentration-controlled, comparison of standard (5-day) vs. prolonged (15-day) infusions of etoposide phosphate in small-cell lung cancer.
    Joel S; O'Byrne K; Penson R; Papamichael D; Higgins A; Robertshaw H; Rudd R; Talbot D; Slevin M
    Ann Oncol; 1998 Nov; 9(11):1205-11. PubMed ID: 9862051
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of oral etoposide in patients with hepatocellular carcinoma.
    Aita P; Robieux I; Sorio R; Tumolo S; Corona G; Cannizzaro R; Colussi AM; Boiocchi M; Toffoli G
    Cancer Chemother Pharmacol; 1999; 43(4):287-94. PubMed ID: 10071979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of an etoposide infused over three days: concomitant infusion with cisplatin.
    Minami H; Horio Y; Sakai S; Saka H; Shimokata K
    Jpn J Clin Oncol; 1991 Dec; 21(6):400-5. PubMed ID: 1666659
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of high-dose cyclosporine on etoposide pharmacodynamics in a trial to reverse P-glycoprotein (MDR1 gene) mediated drug resistance.
    Lum BL; Kaubisch S; Fisher GA; Brown BW; Sikic BI
    Cancer Chemother Pharmacol; 2000; 45(4):305-11. PubMed ID: 10755319
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.